> 89 Tratamiento sistémico del cáncer de mama 11. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016;17(4):425. 12. Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot XB, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. J Clin Oncol. 2017;35(25):2875. 13. Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, et al. Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2018;379(20):1926-36. 14. Slamon DJ, Neven P, Chia S, Fasching PA, de Laurentiis M, Im SA, et al. (2020). Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020;382(6):514-24. 15. Beresford M, Tumur I, Chakrabarti J, Barden J, Rao N, Makris A, et al. A qualitative systematic review of the evidence base for non-cross-resistance between steroidal and non-steroidal aromatase inhibitors in metastatic breast cancer. Clin Oncol (R Coll Radiol). 2011;23(3):209-15. 16. Baselga J, Campone M, Piccart M, Burris HA, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012;366(6):520. 17. Kornblum N. Oral presentation at 2016 San Antonio Breast Cancer Symposium. Available from: https://www. sabcs.org/Portals/SABCS2016/Documents/SABCS-2016-Abstracts.pdf?v=1 18. Schmidt P. Oral presentation at 2017 San Antonio Breast Cancer Symposium. Available from: https://www. sabcs.org/Portals/SABCS2016/Documents/SABCS-2017-Abstracts.pdf 19. Im S-A, Lu Y-S, Bardia A, Harbeck N, Colleoni M, Franke F, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. NEJM. 2019;25;381(4):307-16. 20. U.S. Food and DrugAdministration: FDAexpands ribociclib indication in HR-positive, HER2-negative advanced or metastatic breast cancer. Available from: https://www.fda.gov/drugs/resources-information-approved-drugs/ fda-expands-ribociclib-indication-hr-positive-her2-negative-advanced-or-metastatic-breast-cancer 21. Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, et al. Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results. Oncologist. 2017;22(9):1028. 22. Neven P, Rugo HS, Tolaney SM, Iwata H, Toi Masakazu, et al. Abemaciclib for pre/perimenopausal women with HR+, HER2- advanced breast cancer. J Clin Oncol. 2018;36S:ASCO #1002. 23. ESMO. Extended indication concerns treatment of male patients. Available from: https://www.esmo.org/oncology-news/FDA-Expands-Approved-Use-of-Palbociclib-for- Metastatic-Breast-Cancer 24. Piccart-Gebhart MJ, Burzykowski T, Buyse M, Sledge G, Carmichael J, Lück HJ, et al. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer. J Clin Oncol. 2008;26(12):1980. 25. Ciruelos E, Pérez-García JM, Gavilá J, RodríguezA, de laHaba-Rodríguez J.MaintenanceTherapy inHER2-Negative Metastatic Breast Cancer: A New Approach for an old Concept. Clin Drug Investig. 2019;39(7):595-606. 26. Oshaughnessy JA, Blum J, Moiseyenko V, Jones SE, Miles D, Bell D, Rosso R, et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) vs. a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol. 2001;12(9):1247. 27. Vogel C, O’Rourke M, Winer E, Hochster H, Chang A, Adamkiewicz B, et al. Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol. 1999;10(4):397. 28. Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, et al. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCAMutation. N Engl J Med. 2017;377(6):523. 29. Litton JK, Rugo HS, Ettl J, Hurvitz SA, Gonçalves A, Lee KH, Fehrenbacher L et al. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCAMutation. N Engl J Med. 2018 Aug 23;379(8):753-63.
RkJQdWJsaXNoZXIy MTQzMjMwMg==